156.19
price down icon0.75%   -1.18
after-market アフターアワーズ: 156.84 0.65 +0.42%
loading
前日終値:
$157.37
開ける:
$157.32
24時間の取引高:
7.77M
Relative Volume:
1.31
時価総額:
$193.67B
収益:
$29.79B
当期純損益:
$9.22B
株価収益率:
21.25
EPS:
7.3494
ネットキャッシュフロー:
$10.23B
1週間 パフォーマンス:
+3.32%
1か月 パフォーマンス:
+5.76%
6か月 パフォーマンス:
+12.73%
1年 パフォーマンス:
+32.53%
1日の値動き範囲:
Value
$155.62
$157.57
1週間の範囲:
Value
$147.26
$160.51
52週間の値動き範囲:
Value
$114.02
$160.51

Gilead Sciences Inc Stock (GILD) Company Profile

Name
名前
Gilead Sciences Inc
Name
セクター
Healthcare (1051)
Name
電話
(650) 574-3000
Name
住所
333 LAKESIDE DR, FOSTER CITY, CA
Name
職員
17,000
Name
Twitter
@GileadSciences
Name
次回の収益日
2026-10-29
Name
最新のSEC提出書
Name
GILD's Discussions on Twitter

Compare GILD vs LLY, JNJ, ABBV, MRK, NVS

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
GILD icon
GILD
Gilead Sciences Inc
156.19 193.67B 29.79B 9.22B 10.23B 7.3494
LLY icon
LLY
Lilly Eli Co
1,257.03 1.12T 72.25B 25.28B 10.37B 27.78
JNJ icon
JNJ
Johnson Johnson
255.56 615.87B 97.93B 21.04B 17.80B 8.6278
ABBV icon
ABBV
Abbvie Inc
285.42 504.37B 62.82B 3.60B 19.98B 2.0274
MRK icon
MRK
Merck Co Inc
145.95 360.08B 65.51B 8.93B 14.12B 3.5532
NVS icon
NVS
Novartis Ag Adr
150.62 286.29B 54.66B 13.58B 16.05B 7.0171

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-07-21 ダウングレード Leerink Partners Outperform → Market Perform
2026-07-06 アップグレード HSBC Securities Hold → Buy
2026-05-20 アップグレード Maxim Group Hold → Buy
2026-03-10 開始されました Jefferies Buy
2026-02-20 開始されました Barclays Equal Weight
2026-02-11 繰り返されました Needham Buy
2026-01-07 再開されました UBS Buy
2025-11-24 再開されました Truist Buy
2025-11-13 開始されました Scotiabank Sector Outperform
2025-08-19 アップグレード Daiwa Securities Neutral → Outperform
2025-08-08 アップグレード Truist Hold → Buy
2025-07-25 アップグレード Needham Hold → Buy
2025-04-22 再開されました Cantor Fitzgerald Overweight
2025-03-04 繰り返されました Oppenheimer Outperform
2025-02-18 アップグレード Deutsche Bank Hold → Buy
2025-02-13 アップグレード DZ Bank Hold → Buy
2025-01-10 アップグレード Morgan Stanley Equal-Weight → Overweight
2024-12-10 再開されました BofA Securities Buy
2024-11-15 開始されました Wolfe Research Outperform
2024-11-14 開始されました Citigroup Buy
2024-11-08 ダウングレード Maxim Group Buy → Hold
2024-10-21 アップグレード Leerink Partners Market Perform → Outperform
2024-10-17 開始されました Bernstein Outperform
2024-10-07 アップグレード Wells Fargo Equal Weight → Overweight
2024-07-08 アップグレード Raymond James Mkt Perform → Outperform
2024-05-01 繰り返されました Maxim Group Buy
2024-04-24 アップグレード HSBC Securities Reduce → Hold
2024-02-22 ダウングレード Truist Buy → Hold
2023-11-09 開始されました Deutsche Bank Hold
2023-09-08 アップグレード BofA Securities Neutral → Buy
2023-09-06 開始されました HSBC Securities Reduce
2023-07-24 繰り返されました Barclays Equal Weight
2023-05-16 アップグレード BMO Capital Markets Market Perform → Outperform
2023-04-28 再開されました Piper Sandler Overweight
2023-01-03 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2022-12-13 再開されました BofA Securities Neutral
2022-12-09 ダウングレード DZ Bank Buy → Hold
2022-10-31 アップグレード Barclays Underweight → Equal Weight
2022-10-28 繰り返されました BMO Capital Markets Market Perform
2022-10-28 繰り返されました Cowen Outperform
2022-10-28 繰り返されました JP Morgan Overweight
2022-10-28 繰り返されました Jefferies Buy
2022-10-28 アップグレード Piper Sandler Neutral → Overweight
2022-10-28 繰り返されました RBC Capital Mkts Outperform
2022-10-28 アップグレード Truist Hold → Buy
2022-10-28 繰り返されました Wells Fargo Equal Weight
2022-10-04 アップグレード JP Morgan Neutral → Overweight
2022-07-13 開始されました Cantor Fitzgerald Neutral
2022-05-23 開始されました SVB Leerink Mkt Perform
2022-02-28 ダウングレード BMO Capital Markets Outperform → Market Perform
2022-02-02 繰り返されました BMO Capital Markets Outperform
2022-02-02 繰り返されました BofA Securities Neutral
2022-02-02 繰り返されました RBC Capital Mkts Outperform
2022-02-02 繰り返されました Truist Hold
2022-02-02 繰り返されました Wells Fargo Equal Weight
2022-01-28 アップグレード Argus Hold → Buy
2022-01-06 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-12-09 再開されました Wells Fargo Equal Weight
2021-12-06 開始されました Goldman Neutral
2021-11-19 アップグレード BMO Capital Markets Market Perform → Outperform
2021-11-19 再開されました Piper Sandler Neutral
2021-10-20 再開されました Cowen Outperform
2021-07-30 繰り返されました BMO Capital Markets Market Perform
2021-07-30 繰り返されました RBC Capital Mkts Outperform
2021-04-01 アップグレード Bernstein Mkt Perform → Outperform
2021-03-30 アップグレード Redburn Neutral → Buy
2021-01-19 アップグレード Morgan Stanley Equal-Weight → Overweight
2021-01-04 アップグレード Guggenheim Neutral → Buy
2020-11-03 再開されました Morgan Stanley Equal-Weight
2020-10-28 開始されました UBS Neutral
2020-09-30 再開されました Jefferies Buy
2020-09-15 アップグレード Maxim Group Hold → Buy
2020-07-31 繰り返されました Credit Suisse Neutral
2020-07-31 繰り返されました Morgan Stanley Equal-Weight
2020-07-31 繰り返されました Piper Sandler Overweight
2020-07-31 繰り返されました RBC Capital Mkts Outperform
2020-07-31 繰り返されました SunTrust Hold
2020-07-31 繰り返されました Wells Fargo Equal Weight
2020-07-20 アップグレード Credit Suisse Underperform → Neutral
2020-06-03 アップグレード SVB Leerink Mkt Perform → Outperform
2020-05-26 アップグレード SunTrust Sell → Hold
2020-05-01 ダウングレード JP Morgan Overweight → Neutral
2020-05-01 ダウングレード Raymond James Outperform → Mkt Perform
2020-05-01 ダウングレード SunTrust Hold → Sell
2020-04-27 ダウングレード UBS Buy → Neutral
2020-04-20 ダウングレード BMO Capital Markets Outperform → Market Perform
2020-04-20 ダウングレード Wells Fargo Overweight → Equal Weight
2020-04-17 ダウングレード CFRA Hold → Sell
すべてを表示

Gilead Sciences Inc (GILD) 最新ニュース

pulisher
04:05 AM

Gilead Sciences, Inc. $GILD Shares Sold by Curated Wealth Partners LLC - MarketBeat

04:05 AM
pulisher
03:52 AM

Could Gilead Sciences (NASDAQ:GILD) Be in Focus After Wall Street’s Latest Rotation? - Kalkine Media

03:52 AM
pulisher
03:07 AM

Gilead Sciences, Inc. $GILD Stock Sold by Assenagon Asset Management S.A. - MarketBeat

03:07 AM
pulisher
12:25 PM

Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 - BioSpace

12:25 PM
pulisher
Oct 15, 2026

Gilead Sciences (GILD) Rises Higher Than Market: Key Facts - Yahoo Finance

Oct 15, 2026
pulisher
Oct 15, 2026

Gilead Sciences (GILD) Rises Higher Than Market: Key Facts - Zacks Investment Research

Oct 15, 2026
pulisher
Oct 15, 2026

Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 - Business Wire

Oct 15, 2026
pulisher
Oct 15, 2026

Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth? - Zacks Investment Research

Oct 15, 2026
pulisher
Oct 15, 2026

Gilead Sciences Inc Stock (GILD) Moved Up by 3.67% on Oct 15: Key Drivers Unveiled - TradingKey

Oct 15, 2026
pulisher
Oct 15, 2026

Gilead Sciences (NASDAQ:GILD) Hits New 52-Week HighHere's What Happened - MarketBeat

Oct 15, 2026
pulisher
Oct 15, 2026

Gilead Sciences stock hits all-time high at 157.32 USD - Investing.com

Oct 15, 2026
pulisher
Oct 15, 2026

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - Zacks Investment Research

Oct 15, 2026
pulisher
Oct 15, 2026

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Oct 15, 2026
pulisher
Oct 14, 2026

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 14, 2026
pulisher
Oct 14, 2026

What Does Gilead Sciences (GILD) Gain From Its New Solid Tumor Partnership? - Yahoo Finance

Oct 14, 2026
pulisher
Oct 14, 2026

Gilead snags equity stake in Vir with up to $1.87B deal for three T cell engagers - BioSpace

Oct 14, 2026
pulisher
Oct 14, 2026

Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal - Reuters

Oct 14, 2026
pulisher
Oct 14, 2026

Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors - Business Wire

Oct 14, 2026
pulisher
Oct 13, 2026

Gilead Sciences Inc. stock outperforms competitors despite losses on the day - MarketWatch

Oct 13, 2026
pulisher
Oct 13, 2026

Earnings Preview: What to Expect From Gilead Sciences’ Report - Barchart.com

Oct 13, 2026
pulisher
Oct 13, 2026

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? - Zacks Investment Research

Oct 13, 2026
pulisher
Oct 12, 2026

Gilead Sciences' Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says - Yahoo Finance

Oct 12, 2026
pulisher
Oct 12, 2026

Can Gilead (GILD) Stock Continue Rising in 2027? - Yahoo Finance

Oct 12, 2026
pulisher
Oct 12, 2026

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises - Zacks Investment Research

Oct 12, 2026
pulisher
Oct 12, 2026

BofA raises Gilead Sciences stock price target on growth outlook By Investing.com - Investing.com India

Oct 12, 2026
pulisher
Oct 12, 2026

RBC raised target for Gilead Sciences stock to USD 126.00 - ad-hoc-news.de

Oct 12, 2026
pulisher
Oct 11, 2026

Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH? - The Motley Fool

Oct 11, 2026
pulisher
Oct 11, 2026

Gilead Has Outperformed the S&P 500. But is its Valuation Still Attractive? - Yahoo Finance

Oct 11, 2026
pulisher
Oct 11, 2026

Is Gilead Sciences (GILD) Undervalued After Strong Q2 Sales? - Yahoo Finance

Oct 11, 2026
pulisher
Oct 09, 2026

Gilead Sciences (GILD) Laps the Stock Market: Here's Why - Zacks Investment Research

Oct 09, 2026
pulisher
Oct 09, 2026

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 09, 2026
pulisher
Oct 09, 2026

RBC raises target for Gilead Sciences stock to USD 126.00 - AD HOC NEWS

Oct 09, 2026
pulisher
Oct 09, 2026

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings - Zacks Investment Research

Oct 09, 2026
pulisher
Oct 08, 2026

Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD) - Yahoo! Finance Canada

Oct 08, 2026
pulisher
Oct 08, 2026

Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD) - Yahoo Finance

Oct 08, 2026
pulisher
Oct 08, 2026

Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD) - Yahoo Finance

Oct 08, 2026
pulisher
Oct 08, 2026

Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat

Oct 08, 2026
pulisher
Oct 08, 2026

Cantor Fitzgerald Reaffirms Overweight Rating for Gilead Sciences (NASDAQ:GILD) - MarketBeat

Oct 08, 2026
pulisher
Oct 07, 2026

Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD) - TradingView

Oct 07, 2026
pulisher
Oct 07, 2026

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 07, 2026
pulisher
Oct 07, 2026

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 07, 2026
pulisher
Oct 07, 2026

Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Truist Financial Analyst Says - MarketBeat

Oct 07, 2026
pulisher
Oct 07, 2026

Gilead Sciences (NASDAQ:GILD) Stock Gets Price Target Boost from JPMorgan Chase & Co. - MarketBeat

Oct 07, 2026
pulisher
Oct 07, 2026

U.S. Stocks Slip Ahead of Fed Minutes; Gilead Sciences (GILD) Ga - GuruFocus

Oct 07, 2026
pulisher
Oct 07, 2026

Gilead Sciences (NASDAQ:GILD) Stock Price Target Cut by Morgan Stanley - MarketBeat

Oct 07, 2026
pulisher
Oct 07, 2026

Gilead Sciences Is Maintained at Overweight by Morgan Stanley - Moomoo

Oct 07, 2026
pulisher
Oct 07, 2026

Gilead Sciences stock gains 2.57 percent after AI agreement expands - AD HOC NEWS

Oct 07, 2026
pulisher
Oct 07, 2026

Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX) - Benzinga

Oct 07, 2026
pulisher
Oct 07, 2026

JPMorgan Adjusts Price Target on Gilead Sciences to $170 From $160 - marketscreener.com

Oct 07, 2026
pulisher
Oct 07, 2026

Gilead Sciences signs five-year DevOps agreement with Cognizant - Pharmaceutical Technology

Oct 07, 2026

Gilead Sciences Inc (GILD) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Gilead Sciences Inc (GILD) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Mercier Johanna
Chief Comm & Corp Aff Officer
Oct 15 '26
Sale
156.22
3,000
468,660
113,684
JOHANNA MERCIER
Officer
Oct 15 '26
Proposed Sale
156.22
3,000
468,660
0
ANDREW DICKINSON
Officer
Oct 15 '26
Proposed Sale
156.22
3,000
468,660
0
O'Day Daniel Patrick
Chairman & CEO
Oct 01 '26
Sale
147.90
15,000
2,218,508
566,683
ANDREW DICKINSON
Officer
Sep 15 '26
Proposed Sale
145.29
3,000
435,870
0
Mercier Johanna
Chief Comm & Corp Aff Officer
Sep 15 '26
Sale
144.22
3,000
432,646
116,684
Dickinson Andrew D
Chief Financial Officer
Sep 15 '26
Sale
145.29
3,000
435,870
164,096
JOHANNA MERCIER
Officer
Sep 15 '26
Proposed Sale
144.22
3,000
432,646
0
O'Day Daniel Patrick
Chairman & CEO
Sep 01 '26
Sale
148.64
15,000
2,229,592
577,133
WELTERS ANTHONY
Director
Aug 26 '26
Sale
148.62
18,000
2,675,220
12,894
NVO NVO
$38.83
price down icon 0.99%
PFE PFE
$29.58
price up icon 0.48%
$432.49
price down icon 0.35%
AZN AZN
$165.41
price down icon 0.76%
BMY BMY
$59.75
price down icon 1.35%
NVS NVS
$150.62
price up icon 0.16%
大文字化:     |  ボリューム (24 時間):